Efficacy of prophylactic Immucothel in patients pretreated with conventional drugs to prevent recurrence of superficial bladder carcinoma

Eur Urol. 2000:37 Suppl 3:50-3. doi: 10.1159/000052393.

Abstract

Objectives: Fifty patients enrolled in clinical trials with Immucothel((R)) were reevaluated for their disease-free intervals.

Methods: Of the 37 evaluable patients, 16 had received mitomycin C, 3 bacillus Calmette-Guérin, 3 Adriamycin and 15 miscellaneous pretreatments prior to Immucothel. They thus served as their own controls.

Results: Although their prognosis was worse at the time when Immucothel therapy was started than at the time of initiation of pretreatment, the mean recurrence-free intervals of all patients increased from 17.0 months under pretreatment to 35.1 months under Immucothel.

Conclusion: The difference was statistically significant (Wilcoxon matched-pairs signed-ranks test).

Publication types

  • Comparative Study

MeSH terms

  • Adjuvants, Immunologic / therapeutic use
  • Aged
  • Aged, 80 and over
  • Antibiotics, Antineoplastic / therapeutic use
  • BCG Vaccine / therapeutic use
  • Female
  • Humans
  • Male
  • Middle Aged
  • Mitomycin / therapeutic use
  • Neoplasm Recurrence, Local / drug therapy*
  • Neoplasm Recurrence, Local / prevention & control*
  • Urinary Bladder Neoplasms / drug therapy*
  • Urinary Bladder Neoplasms / prevention & control*

Substances

  • Adjuvants, Immunologic
  • Antibiotics, Antineoplastic
  • BCG Vaccine
  • Mitomycin